fbpx

Newlake Capital Q4 Earnings, Germany Update, And FL Hemp Bill

TDR’s Trade To Black Podcasts are going to be action packed this week! There’s a lot happening in the cannabis industry—hey it’s earnings season, and you aren’t going to want to miss out. For today’s episode, we’ve got $MSOS Monday with Dan Ahrens, Managing Director & Chief Operating Officer of AdvisorShares ETFs, plus a Q4 earnings analysis with our featured interviewee, Anthony Coniglio, CEO of NewLake Capital. Get ready for exclusives you only get on TDR’s Trade To Black podcast.

NewLake Capital Partners provides real estate capital to state-licensed cannabis operators through sale-leaseback transactions, third-party purchases, and funding for build-to-suit projects. We’re kicking off the podcast with a look at their Q4 and full-year earnings, and they had some big numbers to share.

Among some of the highlights of Newlake’s Q4 earnings, the portfolio generated a total of $13m in revenue which was a 6.4% year over year. Also, on March 8, NewLake’s board of directors raised the Q1 2024 cash dividend to $0.41 per share of common stock, equivalent to a $1.64 per share annualized dividend. Anthony Coniglio joins Trade To Black to talk about everything an investor needs to know.

Jumping Into The Wire with some of the latest headlines, Florida’s state legislature has approved a bill to regulate THC products derived from hemp. This is the psychoactive compound found in cannabis products, and under the measure, THC cannot exceed 5mg per serving or 50mg per package.

In Germany, despite the vote to legalize, a committee is now recommending changes to the bill. There’s some concerns that this could just slow the process down even more.

Hear our thoughts on both headlines before we invite Dan Ahrens in to talk $MSOS Monday. As a heads up, there’s going to be a lot of earnings reports coming up this week, so be sure to like, subscribe, and follow so won’t miss any one of these exciting episodes.


You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More